English
简体中文
Total: £ 56.28
Published Date: 2025-06-17 | Pages: 125 | Tables: 127 | Medical Care
In 2024, the global market size of Hemophilia Gene Therapy was estimated to be worth US$ million and is forecast to reach approximately US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.
Global Hemophilia Gene Therapy key players include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Hemophilia Gene Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemophilia Gene Therapy.
The Hemophilia Gene Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hemophilia Gene Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hemophilia Gene Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Spark Therapeutics
Ultragenyx
Shire PLC
Sangamo Therapeutics
Bioverativ
BioMarin
uniQure
Freeline Therapeutics
Segment by Type
Hemophilia A
Hemophilia B
Segment by Application
Hemophilia A Gene Therapy
Hemophilia B Gene Therapy
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Hemophilia Gene Therapy in global and regional level.
Chapter 3: Detailed analysis of Hemophilia Gene Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hemophilia Gene Therapy revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Hemophilia Gene Therapy Product Introduction
1.2 Market by Type
1.2.1 Global Hemophilia Gene Therapy Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Hemophilia A
1.2.3 Hemophilia B
1.3 Market by Application
1.3.1 Global Hemophilia Gene Therapy Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Hemophilia A Gene Therapy
1.3.3 Hemophilia B Gene Therapy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Hemophilia Gene Therapy Market Size Estimates and Forecasts
2.2 Hemophilia Gene Therapy Market Size by Region: 2024 Versus 2031
2.2.1 Global Hemophilia Gene Therapy Revenue by Region: 2020-2025
2.2.2 Global Hemophilia Gene Therapy Revenue Forecast by Region (2026-2031)
2.2.3 Global Hemophilia Gene Therapy Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Hemophilia Gene Therapy Revenue by Type (2020-2031)
3.1.2 Global Hemophilia Gene Therapy Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Hemophilia Gene Therapy Revenue by Application (2020-2031)
3.2.2 Global Hemophilia Gene Therapy Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Hemophilia A of Hemophilia Gene Therapy Revenue Market Share by Application
3.3.2 Hemophilia B of Hemophilia Gene Therapy Revenue Market Share by Application
4 Global Hemophilia Gene Therapy by Company
4.1 Global Hemophilia Gene Therapy Revenue by Company (2020-2025)
4.2 Global Hemophilia Gene Therapy Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Hemophilia Gene Therapy Companies around the World: Ranking by Revenue
4.3.2 Global Hemophilia Gene Therapy Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Hemophilia Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Hemophilia Gene Therapy Companies Headquarters & Product Type
4.4.1 Global Hemophilia Gene Therapy Companies Headquarters
4.4.2 Date of International Companies Enter into Hemophilia Gene Therapy Market
4.4.3 Global Hemophilia Gene Therapy Companies Product & Service
4.4.4 Hemophilia A Revenue Market Share of Hemophilia Gene Therapy by Company
4.4.5 Hemophilia B Revenue Market Share of Hemophilia Gene Therapy by Company
4.5 Global Hemophilia Gene Therapy Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Spark Therapeutics
5.1.1 Spark Therapeutics Corporation Information
5.1.2 Spark Therapeutics Description, Business Overview
5.1.3 Spark Therapeutics Hemophilia Gene Therapy Products Offered
5.1.4 Spark Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (2020-2025)
5.1.5 Spark Therapeutics Hemophilia Gene Therapy Revenue by Product in 2024
5.1.6 Spark Therapeutics Hemophilia Gene Therapy Revenue by Application in 2024
5.1.7 Spark Therapeutics Hemophilia Gene Therapy Revenue by Geographic Area in 2024
5.1.8 Spark Therapeutics Recent Developments
5.2 Ultragenyx
5.2.1 Ultragenyx Corporation Information
5.2.2 Ultragenyx Description, Business Overview
5.2.3 Ultragenyx Hemophilia Gene Therapy Products Offered
5.2.4 Ultragenyx Hemophilia Gene Therapy Revenue and Gross Margin (2020-2025)
5.2.5 Ultragenyx Hemophilia Gene Therapy Revenue by Product in 2024
5.2.6 Ultragenyx Hemophilia Gene Therapy Revenue by Application in 2024
5.2.7 Ultragenyx Hemophilia Gene Therapy Revenue by Geographic Area in 2024
5.2.8 Ultragenyx Recent Developments
5.3 Shire PLC
5.3.1 Shire PLC Corporation Information
5.3.2 Shire PLC Description, Business Overview
5.3.3 Shire PLC Hemophilia Gene Therapy Products Offered
5.3.4 Shire PLC Hemophilia Gene Therapy Revenue and Gross Margin (2020-2025)
5.3.5 Shire PLC Hemophilia Gene Therapy Revenue by Product in 2024
5.3.6 Shire PLC Hemophilia Gene Therapy Revenue by Application in 2024
5.3.7 Shire PLC Hemophilia Gene Therapy Revenue by Geographic Area in 2024
5.3.8 Shire PLC Recent Developments
5.4 Sangamo Therapeutics
5.4.1 Sangamo Therapeutics Corporation Information
5.4.2 Sangamo Therapeutics Description, Business Overview
5.4.3 Sangamo Therapeutics Hemophilia Gene Therapy Products Offered
5.4.4 Sangamo Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (2020-2025)
5.4.5 Sangamo Therapeutics Hemophilia Gene Therapy Revenue by Product in 2024
5.4.6 Sangamo Therapeutics Hemophilia Gene Therapy Revenue by Application in 2024
5.4.7 Sangamo Therapeutics Hemophilia Gene Therapy Revenue by Geographic Area in 2024
5.4.8 Sangamo Therapeutics Recent Developments
5.5 Bioverativ
5.5.1 Bioverativ Corporation Information
5.5.2 Bioverativ Description, Business Overview
5.5.3 Bioverativ Hemophilia Gene Therapy Products Offered
5.5.4 Bioverativ Hemophilia Gene Therapy Revenue and Gross Margin (2020-2025)
5.5.5 Bioverativ Hemophilia Gene Therapy Revenue by Product in 2024
5.5.6 Bioverativ Hemophilia Gene Therapy Revenue by Application in 2024
5.5.7 Bioverativ Hemophilia Gene Therapy Revenue by Geographic Area in 2024
5.5.8 Bioverativ Recent Developments
5.6 BioMarin
5.6.1 BioMarin Corporation Information
5.6.2 BioMarin Description, Business Overview
5.6.3 BioMarin Hemophilia Gene Therapy Products Offered
5.6.4 BioMarin Hemophilia Gene Therapy Revenue and Gross Margin (2020-2025)
5.6.5 BioMarin Hemophilia Gene Therapy Revenue by Product in 2024
5.6.6 BioMarin Hemophilia Gene Therapy Revenue by Application in 2024
5.6.7 BioMarin Hemophilia Gene Therapy Revenue by Geographic Area in 2024
5.6.8 BioMarin Recent Developments
5.7 uniQure
5.7.1 uniQure Corporation Information
5.7.2 uniQure Description, Business Overview
5.7.3 uniQure Hemophilia Gene Therapy Products Offered
5.7.4 uniQure Hemophilia Gene Therapy Revenue and Gross Margin (2020-2025)
5.7.5 uniQure Hemophilia Gene Therapy Revenue by Product in 2024
5.7.6 uniQure Hemophilia Gene Therapy Revenue by Application in 2024
5.7.7 uniQure Hemophilia Gene Therapy Revenue by Geographic Area in 2024
5.7.8 uniQure Recent Developments
5.8 Freeline Therapeutics
5.8.1 Freeline Therapeutics Corporation Information
5.8.2 Freeline Therapeutics Description, Business Overview
5.8.3 Freeline Therapeutics Hemophilia Gene Therapy Products Offered
5.8.4 Freeline Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (2020-2025)
5.8.5 Freeline Therapeutics Hemophilia Gene Therapy Revenue by Product in 2024
5.8.6 Freeline Therapeutics Hemophilia Gene Therapy Revenue by Application in 2024
5.8.7 Freeline Therapeutics Hemophilia Gene Therapy Revenue by Geographic Area in 2024
5.8.8 Freeline Therapeutics Recent Developments
6 North America
6.1 North America Hemophilia Gene Therapy Market Size YoY Growth 2020-2031
6.2 North America Hemophilia Gene Therapy Market Facts & Figures by Country (2020-2031)
6.3 North America Hemophilia Gene Therapy Revenue by Type (2020-2025)
6.4 North America Hemophilia Gene Therapy Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Hemophilia Gene Therapy Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Hemophilia Gene Therapy Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Hemophilia Gene Therapy Revenue by Type (2020-2025)
7.4 Asia-Pacific Hemophilia Gene Therapy Revenue by Application (2020-2025)
8 Europe
8.1 Europe Hemophilia Gene Therapy Market Size YoY Growth 2020-2031
8.2 Europe Hemophilia Gene Therapy Market Facts & Figures by Country (2020-2031)
8.3 Europe Hemophilia Gene Therapy Revenue by Type (2020-2025)
8.4 Europe Hemophilia Gene Therapy Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Hemophilia Gene Therapy Market Size YoY Growth 2020-2031
9.2 Latin America Hemophilia Gene Therapy Market Facts & Figures by Country (2020-2031)
9.3 Latin America Hemophilia Gene Therapy Revenue by Type (2020-2025)
9.4 Latin America Hemophilia Gene Therapy Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Hemophilia Gene Therapy Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Hemophilia Gene Therapy Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Hemophilia Gene Therapy Revenue by Type (2020-2025)
10.4 Middle East and Africa Hemophilia Gene Therapy Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Hemophilia Gene Therapy Supply Chain Analysis
11.2 Hemophilia Gene Therapy Key Raw Materials and Upstream Suppliers
11.3 Hemophilia Gene Therapy Clients Analysis
11.4 Hemophilia Gene Therapy Sales Channel and Sales Model Analysis
11.4.1 Hemophilia Gene Therapy Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Hemophilia Gene Therapy Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Hemophilia Gene Therapy Distributors
12 Hemophilia Gene Therapy Market Dynamics
12.1 Hemophilia Gene Therapy Industry Trends
12.2 Hemophilia Gene Therapy Market Drivers
12.3 Hemophilia Gene Therapy Market Challenges
12.4 Hemophilia Gene Therapy Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global Hemophilia Gene Therapy Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Hemophilia Gene Therapy Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Hemophilia Gene Therapy Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Hemophilia Gene Therapy Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Hemophilia Gene Therapy Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 6. Global Hemophilia Gene Therapy Revenue by Type (2020-2025) & (US$ Million)
Table 7. Global Hemophilia Gene Therapy Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 8. Global Hemophilia Gene Therapy Revenue by Application (2020-2025) & (US$ Million)
Table 9. Global Hemophilia Gene Therapy Revenue Forecast by Application (2026-2031) & (US$ Million)
Table 10. Hemophilia Gene Therapy Revenue by Company (2020-2025) & (US$ Million)
Table 11. Hemophilia Gene Therapy Revenue Share by Company (2020-2025)
Table 12. Ranking of Global Top Hemophilia Gene Therapy Players by Revenue (US$ Million) in 2024
Table 13. Global Hemophilia Gene Therapy Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 14. Global Hemophilia Gene Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hemophilia Gene Therapy as of 2024)
Table 15. Global Hemophilia Gene Therapy Companies Headquarters
Table 16. Date of International Companies Enter into Hemophilia Gene Therapy Market
Table 17. Global Hemophilia Gene Therapy Companies Product & Service
Table 18. Global Hemophilia Gene Therapy Mergers & Acquisitions, Expansion Plans
Table 19. Spark Therapeutics Corporation Information
Table 20. Spark Therapeutics Description and Business Overview
Table 21. Spark Therapeutics Hemophilia Gene Therapy Product
Table 22. Spark Therapeutics Hemophilia Gene Therapy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 23. Spark Therapeutics Revenue Proportion of Hemophilia Gene Therapy by Product in 2024
Table 24. Spark Therapeutics Revenue Proportion of Hemophilia Gene Therapy by Application in 2024
Table 25. Spark Therapeutics Revenue Proportion of Hemophilia Gene Therapy by Geographic Area in 2024
Table 26. Spark Therapeutics Recent Developments
Table 27. Ultragenyx Corporation Information
Table 28. Ultragenyx Description and Business Overview
Table 29. Ultragenyx Hemophilia Gene Therapy Product
Table 30. Ultragenyx Hemophilia Gene Therapy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 31. Ultragenyx Revenue Proportion of Hemophilia Gene Therapy by Product in 2024
Table 32. Ultragenyx Revenue Proportion of Hemophilia Gene Therapy by Application in 2024
Table 33. Ultragenyx Revenue Proportion of Hemophilia Gene Therapy by Geographic Area in 2024
Table 34. Ultragenyx Recent Developments
Table 35. Shire PLC Corporation Information
Table 36. Shire PLC Description and Business Overview
Table 37. Shire PLC Hemophilia Gene Therapy Product
Table 38. Shire PLC Hemophilia Gene Therapy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 39. Shire PLC Revenue Proportion of Hemophilia Gene Therapy by Product in 2024
Table 40. Shire PLC Revenue Proportion of Hemophilia Gene Therapy by Application in 2024
Table 41. Shire PLC Revenue Proportion of Hemophilia Gene Therapy by Geographic Area in 2024
Table 42. Shire PLC Recent Developments
Table 43. Sangamo Therapeutics Corporation Information
Table 44. Sangamo Therapeutics Description and Business Overview
Table 45. Sangamo Therapeutics Hemophilia Gene Therapy Product
Table 46. Sangamo Therapeutics Hemophilia Gene Therapy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Sangamo Therapeutics Revenue Proportion of Hemophilia Gene Therapy by Product in 2024
Table 48. Sangamo Therapeutics Revenue Proportion of Hemophilia Gene Therapy by Application in 2024
Table 49. Sangamo Therapeutics Revenue Proportion of Hemophilia Gene Therapy by Geographic Area in 2024
Table 50. Sangamo Therapeutics Recent Developments
Table 51. Bioverativ Corporation Information
Table 52. Bioverativ Description and Business Overview
Table 53. Bioverativ Hemophilia Gene Therapy Product
Table 54. Bioverativ Hemophilia Gene Therapy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 55. Bioverativ Revenue Proportion of Hemophilia Gene Therapy by Product in 2024
Table 56. Bioverativ Revenue Proportion of Hemophilia Gene Therapy by Application in 2024
Table 57. Bioverativ Revenue Proportion of Hemophilia Gene Therapy by Geographic Area in 2024
Table 58. Bioverativ Recent Developments
Table 59. BioMarin Corporation Information
Table 60. BioMarin Description and Business Overview
Table 61. BioMarin Hemophilia Gene Therapy Product
Table 62. BioMarin Hemophilia Gene Therapy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 63. BioMarin Revenue Proportion of Hemophilia Gene Therapy by Product in 2024
Table 64. BioMarin Revenue Proportion of Hemophilia Gene Therapy by Application in 2024
Table 65. BioMarin Revenue Proportion of Hemophilia Gene Therapy by Geographic Area in 2024
Table 66. BioMarin Recent Developments
Table 67. uniQure Corporation Information
Table 68. uniQure Description and Business Overview
Table 69. uniQure Hemophilia Gene Therapy Product
Table 70. uniQure Hemophilia Gene Therapy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 71. uniQure Revenue Proportion of Hemophilia Gene Therapy by Product in 2024
Table 72. uniQure Revenue Proportion of Hemophilia Gene Therapy by Application in 2024
Table 73. uniQure Revenue Proportion of Hemophilia Gene Therapy by Geographic Area in 2024
Table 74. uniQure Recent Developments
Table 75. Freeline Therapeutics Corporation Information
Table 76. Freeline Therapeutics Description and Business Overview
Table 77. Freeline Therapeutics Hemophilia Gene Therapy Product
Table 78. Freeline Therapeutics Hemophilia Gene Therapy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 79. Freeline Therapeutics Revenue Proportion of Hemophilia Gene Therapy by Product in 2024
Table 80. Freeline Therapeutics Revenue Proportion of Hemophilia Gene Therapy by Application in 2024
Table 81. Freeline Therapeutics Revenue Proportion of Hemophilia Gene Therapy by Geographic Area in 2024
Table 82. Freeline Therapeutics Recent Developments
Table 83. North America Hemophilia Gene Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 84. North America Hemophilia Gene Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 85. North America Hemophilia Gene Therapy Revenue by Type (2020-2025) & (US$ Million)
Table 86. North America Hemophilia Gene Therapy Revenue by Application (2020-2025) & (US$ Million)
Table 87. Asia-Pacific Hemophilia Gene Therapy Revenue by Region (2020-2025) & (US$ Million)
Table 88. Asia-Pacific Hemophilia Gene Therapy Revenue by Region (2026-2031) & (US$ Million)
Table 89. Asia-Pacific Hemophilia Gene Therapy Revenue by Type (2020-2025) & (US$ Million)
Table 90. Asia-Pacific Hemophilia Gene Therapy Revenue by Application (2020-2025) & (US$ Million)
Table 91. Europe Hemophilia Gene Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 92. Europe Hemophilia Gene Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 93. Europe Hemophilia Gene Therapy Revenue by Type (2020-2025) & (US$ Million)
Table 94. Europe Hemophilia Gene Therapy Revenue by Application (2020-2025) & (US$ Million)
Table 95. Latin America Hemophilia Gene Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 96. Latin America Hemophilia Gene Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 97. Latin America Hemophilia Gene Therapy Revenue by Type (2020-2025) & (US$ Million)
Table 98. Latin America Hemophilia Gene Therapy Revenue by Application (2020-2025) & (US$ Million)
Table 99. Middle East and Africa Hemophilia Gene Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 100. Middle East and Africa Hemophilia Gene Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 101. Middle East and Africa Hemophilia Gene Therapy Revenue by Type (2020-2025) & (US$ Million)
Table 102. Middle East and Africa Hemophilia Gene Therapy Revenue by Application (2020-2025) & (US$ Million)
Table 103. Hemophilia Gene Therapy Key Raw Materials, Industry Status and Trend
Table 104. Hemophilia Gene Therapy Key Raw Materials and Upstream Suppliers
Table 105. Hemophilia Gene Therapy Clients Status and Trend
Table 106. Hemophilia Gene Therapy Typical Clients
Table 107. Hemophilia Gene Therapy Distributors
Table 108. Hemophilia Gene Therapy Market Trends
Table 109. Hemophilia Gene Therapy Market Drivers
Table 110. Hemophilia Gene Therapy Market Challenges
Table 111. Hemophilia Gene Therapy Market Restraints
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Hemophilia Gene Therapy Product Picture
Figure 2. Global Hemophilia Gene Therapy Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Hemophilia Gene Therapy Revenue Market Share by Type in 2024 & 2031
Figure 4. Hemophilia A Product Picture
Figure 5. Hemophilia B Product Picture
Figure 6. Global Hemophilia Gene Therapy Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 7. Global Hemophilia Gene Therapy Revenue Market Share by Application in 2024 & 2031
Figure 8. Hemophilia A Gene Therapy
Figure 9. Hemophilia B Gene Therapy
Figure 10. Hemophilia Gene Therapy Report Years Considered
Figure 11. Global Hemophilia Gene Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Hemophilia Gene Therapy Market Size (2020-2031) & (US$ Million)
Figure 13. Global Hemophilia Gene Therapy Market Size Market Share by Region: 2024 Versus 2031
Figure 14. Global Hemophilia Gene Therapy Revenue Market Share by Region (2020-2031)
Figure 15. Global Hemophilia Gene Therapy Revenue Market Share Forecast by Type (2020-2031)
Figure 16. Global Hemophilia Gene Therapy Revenue Market Share Forecast by Application (2020-2031)
Figure 17. Hemophilia A of Hemophilia Gene Therapy Revenue Market Share by Application, 2024 VS 2031
Figure 18. Hemophilia B of Hemophilia Gene Therapy Revenue Market Share by Application, 2024 VS 2031
Figure 19. Hemophilia Gene Therapy Revenue Share by Company (2024)
Figure 20. Hemophilia Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 21. Hemophilia A Revenue Proportion by Company in 2024
Figure 22. Hemophilia B Revenue Proportion by Company in 2024
Figure 23. North America Hemophilia Gene Therapy Revenue 2020-2031 (US$ Million)
Figure 24. North America Hemophilia Gene Therapy Revenue Market Share by Type (2020-2025)
Figure 25. North America Hemophilia Gene Therapy Revenue Market Share by Application (2020-2025)
Figure 26. Asia-Pacific Hemophilia Gene Therapy Revenue 2020-2031 (US$ Million)
Figure 27. Asia-Pacific Hemophilia Gene Therapy Revenue Market Share by Region (2020-2031)
Figure 28. Asia-Pacific Hemophilia Gene Therapy Revenue Market Share by Type (2020-2025)
Figure 29. Asia-Pacific Hemophilia Gene Therapy Revenue Market Share by Application (2020-2025)
Figure 30. Europe Hemophilia Gene Therapy Revenue Growth Rate 2020-2031 (US$ Million)
Figure 31. Europe Hemophilia Gene Therapy Revenue Market Share by Country (2020-2031)
Figure 32. Europe Hemophilia Gene Therapy Revenue Market Share by Type (2020-2025)
Figure 33. Europe Hemophilia Gene Therapy Revenue Market Share by Application (2020-2025)
Figure 34. Latin America Hemophilia Gene Therapy Revenue Growth Rate 2020-2031 (US$ Million)
Figure 35. Latin America Hemophilia Gene Therapy Revenue Market Share by Country (2020-2031)
Figure 36. Latin America Hemophilia Gene Therapy Revenue Market Share by Type (2020-2025)
Figure 37. Latin America Hemophilia Gene Therapy Revenue Market Share by Application (2020-2025)
Figure 38. Middle East and Africa Hemophilia Gene Therapy Revenue Growth Rate 2020-2031 (US$ Million)
Figure 39. Middle East and Africa Hemophilia Gene Therapy Revenue Market Share by Country (2020-2031)
Figure 40. Middle East and Africa Hemophilia Gene Therapy Revenue Market Share by Type (2020-2025)
Figure 41. Middle East and Africa Hemophilia Gene Therapy Revenue Market Share by Application (2020-2025)
Figure 42. Hemophilia Gene Therapy Supply Chain (Upstream and Downstream Market)
Figure 43. Global Production Market Share of Hemophilia Gene Therapy Raw Materials by Region in 2024
Figure 44. Hemophilia Gene Therapy Distribution Channels
Figure 45. Global Hemophilia Gene Therapy Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 46. Global Hemophilia Gene Therapy Percentage 2020-2031: Online Sales VS Offline Sales
Figure 47. Bottom-up and Top-down Approaches for This Report
Figure 48. Data Triangulation
Figure 49. Key Executives Interviewed
